Modality
Multispecific
MOA
JAK1i
Target
PSMA
Pathway
PD-1/PD-L1
LGSPompeT2D
Development Pipeline
Preclinical
~Apr 2010
→ ~Jul 2011
Phase 1
~Oct 2011
→ ~Jan 2013
Phase 2
~Apr 2013
→ ~Jul 2014
Phase 3
~Oct 2014
→ ~Jan 2016
NDA/BLA
~Apr 2016
→ ~Jul 2017
Approved
Oct 2017
→ Aug 2029
ApprovedCurrent
NCT03678960
785 pts·T2D
2019-09→2029-08·Not yet recruiting
NCT04528885
2,764 pts·Pompe
2020-12→2028-05·Terminated
NCT05771262
868 pts·T2D
2017-10→2027-03·Recruiting
+1 more trial
5,578 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2027-03-0411mo awayPh3 Readout· T2D
2028-05-102.1y awayPh3 Readout· Pompe
2029-08-063.4y awayPh3 Readout· T2D
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Recruit…
Approved
Not yet…
Approved
Termina…
Approved
Termina…
Catalysts
Ph3 Readout
2027-03-04 · 11mo away
T2D
Ph3 Readout
2028-05-10 · 2.1y away
Pompe
Ph3 Readout
2029-08-06 · 3.4y away
T2D
RecruitingTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03678960 | Approved | T2D | Not yet recr... | 785 | EDSS |
| NCT04528885 | Approved | Pompe | Terminated | 2764 | BodyWt |
| NCT05771262 | Approved | T2D | Recruiting | 868 | FEV1 |
| NCT04904121 | Approved | T2D | Terminated | 1161 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 |